SUPERNUS PHARMACEUTICALS, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 20.50 thousand shares for the 12-month period ending 2014-12-31, per its 10-K filed 2016-03-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2016-03-09
- SUPERNUS PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2014-09-30 was 20.86K shares.
- SUPERNUS PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2014 was 20.50K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|
| 2014-12-31 | 20.50K shares 10-K · filed 2016-03-09 | ||
| 2014-09-30 | 20.86K shares 10-Q · filed 2015-11-09 | 20.91K shares 10-Q · filed 2015-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |